Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Locally Advanced Breast Cancer
Metastatic Breast Cancer
ER Positive Breast Cancer
HER2 Negative Breast Carcinoma

Interventions

DRUG: Palazestrant
DRUG: Letrozole-matching placebo
DRUG: Ribociclib
DRUG: Letrozole
DRUG: Palazestrant matching-placebo

Sponsor

Olema Pharmaceuticals, Inc.

Collaborators

[object Object]